run coming?, page-14

There is a pipeline. Nobody thinks that is not only VF0001 the real product, but we have ocular, complex skin diseases and other applications on this technology. It is not the product that is the winner here, but the technology that fortuitous or not is complex but simple to reproduce. Here we do not speak about something that being an innovation costs 100k to deliver to the patients. Here we have something that costs little to produce and that can be delivered at a very reasonable price to a lot of people.